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N E U R O S C I E N C E
Microglia control small vessel calcification via TREM2
Yvette Zarb1,2*, Sucheta Sridhar1,2†, Sina Nassiri3†, Sebastian Guido Utz4, 
Johanna Schaffenrath1,2, Upasana Maheshwari1,2, Elisabeth J. Rushing5, K. Peter R. Nilsson6, 
Mauro Delorenzi3,7, Marco Colonna8, Melanie Greter4, Annika Keller1,2‡
Microglia participate in central nervous system (CNS) development and homeostasis and are often implicated in 
modulating disease processes. However, less is known about the role of microglia in the biology of the neuro-
vascular unit (NVU). In particular, data are scant on whether microglia are involved in CNS vascular pathology. In this 
study, we use a mouse model of primary familial brain calcification, Pdgfbret/ret, to investigate the role of microglia 
in calcification of the NVU. We report that microglia enclosing vessel calcifications, coined calcification- associated 
microglia, display a distinct activation phenotype. Pharmacological ablation of microglia with the CSF1R inhib-
itor PLX5622 leads to aggravated vessel calcification. Mechanistically, we show that microglia require functional 
TREM2 for controlling vascular calcification. Our results demonstrate that microglial activity in the setting of 
pathological vascular calcification is beneficial. In addition, we identify a previously unrecognized function of 
microglia in halting the expansion of vascular calcification.
INTRODUCTION
Microglia participate in central nervous system (CNS) development 
and homeostasis by regulating neural cell numbers, migration of 
interneurons, as well as promoting connectivity, synapse formation, 
and pruning (1). Microglia are considered the first line of immune 
defense in the brain by monitoring the brain parenchyma under 
homeostatic conditions and resolving cerebral insults (2). However, 
less is known about the function of microglia at the neurovascular 
unit (NVU), which is composed of vascular cells (endothelial and 
mural cells, as well as perivascular fibroblasts and macrophages), 
associated neurons, and glia (3). Microglia have been implicated in 
shaping brain vasculature during development (4). In adults, mi-
croglial processes directly contact the endothelial basement mem-
brane at the NVU (5), and microglia has been shown to maintain 
vascular integrity during various insults such as mechanical injury 
or systemic inflammation (6, 7). Disruption of the NVU is common 
to many neurodegenerative diseases (3); however, studies on microg-
lial function have mainly focused on brain parenchyma and not 
the NVU.
Optimal functioning of the NVU, which mediates functional 
hyperemia, is crucial for cerebral perfusion (3). Blood vessels play 
an integral role in brain development and provide a niche for brain 
stem cells. In addition, cerebral vasculature senses the environment 
and communicates changes to neural tissue, participates in glymphatic 
clearance, and controls immune quiescence in the CNS (8, 9). Ac-
cordingly, dysfunction of the NVU accompanies or may even rep-
resent a primary cause of many neurodegenerative diseases (3). In 
the case of primary familial brain calcification (PFBC), bilateral basal 
ganglia calcification of blood vessels is a key diagnostic criterion. 
The pathogenic mechanism points to a compromised NVU (10). 
PFBC is a clinically and genetically heterogeneous neuropsychiatric 
disorder (composed of psychiatric signs—anxiety and psychosis, 
cognitive impairment, and movement disorders—ataxia, dystonia, and 
parkinsonism) caused by mutations in at least six genes, JAM2, 
MYORG, PDGFB, PDGFRB, SLC20A2, and XPR1 (10, 11). Notably, 
recent studies have estimated the minimal prevalence of PFBC 
ranges from 4 to 6 per 10,000, depending on the causative gene mu-
tation, thus suggesting that PFBC is not a rare disorder and is likely 
underdiagnosed (12). In addition, basal ganglia calcification is a 
common radiological finding, estimated in up to 20% of patients 
undergoing computed tomography (CT) imaging (13). Although 
the effect of cerebral calcification on the NVU and brain parenchyma 
is unknown, peripheral vascular calcification can lead to cardiovas-
cular morbidity and mortality (14). Recent studies have suggested 
the involvement of glia in PFBC pathophysiology (15–17); however, 
functional studies demonstrating the role of glia in cerebral vessel 
calcification pathology are absent.
In this study, we investigated the role of microglia in vascular 
calcification using a mouse model of PFBC. Previously, we described 
that mouse platelet-derived growth factor B (Pdgfb) hypomorphs 
(Pdgfbret/ret) develop brain vessel–associated calcifications similar to 
human PFBC (18). Vascular calcifications in human PFBC and mouse 
models of PFBC were conspicuously encircled by activated microg-
lia (15,  17,  19). In addition, an osteogenic environment with the 
surrounding cells expressing osteoclast markers was recently reported 
(17), although the cellular origin of these cells remains unknown.
Here, we characterize a distinct activation phenotype of microglia 
encircling vascular calcifications in Pdgfbret/ret mice, coined “calcification- 
associated microglia” (CAM). Pharmacological ablation of microglia in 
Pdgfbret/ret mice leads to aggravated calcification of the NVU. In addition, 
we show in wild-type mice and a mouse model of PFBC that ablation of 
microglia leads to the development of axonal spheroids containing bone 
proteins (osteocalcin and osteopontin) in the white matter. Mechanisti-
cally, we show that microglia require functional triggering receptor 
expressed on myeloid cells 2 (TREM2) for controlling vessel-associated 
calcifications, as genetic deletion of Trem2 in Pdgfbret/ret mice exacerbates 
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vascular calcification. In conclusion, our study shows that microglia play 
an important role in modifying vascular calcification in the brain and 
identifies microglia as a potential therapeutic target in PFBC.
RESULTS
Brain vessel–associated calcifications trigger 
an inflammatory environment
Vascular calcification in PFBC elicits a conspicuous glial reaction 
(17–19). To gain insights into inflammatory changes accompanying 
vessel calcifications, we performed transcriptome analysis using RNA 
sequencing (RNA-seq) on tissue enriched with vessel-associated 
calcifications isolated from brains of Pdgfbret/ret mice, a mouse model 
of PFBC. Brain calcifications are autofluorescent (18), which we ex-
ploited to manually isolate calcifications from the brains of Pdgfbret/ret 
animals under a fluorescent stereomicroscope. Noncalcified tissue 
from the same anatomical region (thalamus/midbrain) was also 
collected from control animals (Pdgfbret/wt). This brain region is re-
ferred to as a “calcification-prone region” (Fig. 1A). We also isolated 
tissue from the cortex (referred to as a “non–calcification-prone 
region”) of both Pdgfbret/ret and control animals (Fig. 1A). Principal 
components analysis (PCA) of transcriptomic data showed that 
the first PC accounts for variability due to anatomical differences 
(thalamus/midbrain versus cortex), while the second PC accounts 
for differences between genotypes (fig. S1A). When comparing cal-
cification- and non–calcification-prone brain regions of Pdgfbret/ret 
and control animals, we detected 92 and 94 deregulated genes, re-
spectively [false discovery rate (FDR) < 0.05 and fold change > 2; 
Fig. 1B, fig. S1B, and tables S3 and S4]. Contrasting differentially 
expressed genes in non–calcification-prone and calcification-prone 
regions between Pdgfbret/ret and control animals showed that 74 genes 
were deregulated only in the calcification-prone region (thalamus/
midbrain) and that 60 genes were deregulated only in a non–
calcification-prone region (cortex) (Fig. 1, C and D, and table S5). 
The remaining 26 deregulated genes detected in both regions 
(Fig. 1, C and D, and table S5) concur with previously reported 
vascular transcriptional alterations due to reduced pericyte numbers 
in Pdgfbret/ret mice (20). Enrichment analysis of hallmark pathways 
showed that several inflammatory pathways, such as interfer-
on γ and α pathways, reactive oxygen species pathway, and in-
flammatory response pathway, are enriched in Pdgfbret/ret mice 
compared to controls (Fig. 1E). Several pathways were enriched 
only in calcification-prone regions, such as interleukin-2–signal 
transducer and activator of transcription 5 signaling, unfolded pro-
tein response, and tumor necrosis factor–a signaling via nuclear 
factor kB (fig. S1C). Various significantly deregulated hallmark 
pathways (Fig. 1E and fig. S1C) have been associated with activated 
microglia (e.g., interferon related and complement related) or 
microglia quiescence (e.g., transforming growth factor–b related) 
(21, 22). Notably, Cst7, which encodes a cysteine protease inhibitor 
and is expressed in activated microglia (23), was the top up-regulated 
gene (3.7-fold) in brain regions with calcifications (Fig. 1B and table 
S3). The expression of Cst7 was not detected in either genotype in a 
non–calcification-prone brain region (cortex) or in the calcification- 
prone region of control animals (fig. S1D and tables S3 and S4). To 
further explore the gene signature associated with vascular calcification, 
we performed coexpression network analysis on highly variable genes 
in the RNA-seq dataset (fig. S1E) and identified six modules of pos-
itively correlated genes (fig. S1F and table S6). We found that only 
one module (M4) was associated with the calcified brain region in 
the Pdgfbret/ret mice (Fig. 1F). To summarize the node profiles of the 
M4 module, we examined its intramodular connectivity to identify 
the most highly connected intramodular hub genes (see Materials 
and Methods for details). Intuitively, hub genes can be viewed as 
module representatives that are centrally located in a network rep-
resentation of correlated genes. Among the hub genes within the 
M4 module, we identified Cst7 and Itgax (Fig. 1G), genes induced in 
microglia in neurodegenerative diseases, termed DAM (disease- 
associated microglia), and in aging (23). Furthermore, in addition 
to Cst7 and Itgax, several other genes associated to reactive microglia 
or the DAM signature (e.g., Cd68, Clec7a, and Lpl) were significantly 
up-regulated in the calcified brain regions of Pdgfbret/ret mice (Figs. 1B 
and 2A). However, when comparing up-regulated genes in calcification- 
prone regions in Pdgfbret/ret mice using stringent criteria (FDR < 0.05 
and fold change > 2) with the DAM signature, we found an overlap 
of only six genes (Lpl, Cd68, Tyrobp, Itgax, Cst7, and Clec7a) (fig. S1G). 
The DAM signature was recently reported to overlap with the “prolif-
erative region–associated microglia” (PAM) signature that defines a 
subset of microglia found in the white matter during development 
(24). By comparing the PAM signature with our dataset using the 
same criteria as for the DAM genes, an overlap of seven genes 
(Hmox1, Lpl, Cd68, Slc16a3, Lag3, Tyrobp, and Clec7a) was found 
(fig. S1H). We validated the expression of DAM/PAM signature genes 
TIMP2 (Fig. 2B), CD68 (Fig. 2C), CLEC7A (Fig. 2, D and E), ITGAX 
(Fig. 2F), and CST7 (Fig. 2G) in microglia surrounding vessel-associated 
calcifications with immunohistochemistry. CD68 was expressed by 
microglia and perivascular macrophages (PVM) throughout the brain 
(fig. S2A), but its expression was up-regulated in CAM (Fig. 2C). 
Conspicuous CLEC7A positivity was seen in CAM (Fig. 2D), which 
showed down-regulation of P2YR12, a homeostatic microglia marker, 
and up-regulation of Iba1 (Fig. 2E). CLEC7A expression was also 
seen in a subpopulation of white matter microglial cells (fig. S2B), 
in agreement with reported expression of CLEC7A in white matter 
microglia (25). In addition, single microglial cells with normal mor-
phology in the cortex of Pdgfbret/ret mice showed CLEC7A expression 
(fig. S2C). ITGAX and CST7 were expressed only in CAM and not 
in microglia in other brain regions or in other cell types. Similarly, 
TIMP2 was expressed only by microglia surrounding calcifications 
and in neurons (fig. S2D), as previously reported (26). Thus, CAM 
exhibited an activation profile overlapping with microglia during 
aging, neurodegenerative proteinopathies, and development.
Brain vessel–associated calcifications contain  
protein aggregates
Because the CAM protein expression profile resembles the DAM 
signature reported in b-amyloid plaque–associated microglia in 
Alzheimer’s disease (AD) (Fig. 2) (23) and vascular calcifications 
contain protein deposits such as amyloid b precursor protein (APP) 
and amyloid precursor–like protein 2 (15), we next asked whether 
brain calcifications might also contain amyloid fibrils as b-amyloid 
plaques. To investigate this possibility, we used thioflavin T and 
Congo red, standard stains to detect amyloid fibrils in b-amyloid 
plaques, and a recently developed amyloid-interacting luminescent 
conjugated oligothiophene (LCO), h-HTAA. Vessel-associated cal-
cifications were thioflavin T and Congo red (fig. S3A) negative but 
positive for h-HTAA (fig. S3B) that binds protein aggregates before 
the formation of amyloid fibrils recognized by thioflavin T (27). Thus, 
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lack the b-pleated sheet conformation and structural regularity rec-
ognized by thioflavin T or Congo red.
CAM exhibit a distinct phenotype from DAM
Osteopontin (OPN, Spp1), one of the signature genes defining PAM 
and DAM (23, 24), is deposited in brain calcifications in human PFBC 
and animal models of PFBC (17). We therefore investigated whether 
microglia surrounding calcifications express osteopontin. Immuno-
histochemical visualization of microglia using anti-Iba1 and costaining 
with osteopontin did not confirm osteopontin expression by microglia 
(fig. S4, A and B). Instead, a strong osteopontin expression was seen 
in a subset of glial fibrillary acidic protein (GFAP)–positive, reactive 
astrocytes surrounding or adjacent to calcifications (fig. S4, A and C). Thus, 
in contrast to PAM and DAM, CAM do not up-regulate osteopontin 
expression. Hydroxyapatite, found in vessel-associated calcifications 
(17), and β-amyloid plaques induce formation of the inflammasome in 
macrophages and microglia, respectively (fig. S4D) (28, 29). We therefore 
investigated whether microglia around calcifications express ASC, 
an adaptor protein for inflammasome-mediated caspase-1 activation. 
We could not find ASC positivity in microglia surrounding vessel 
calcifications in Pdgfbret/ret animals (fig. S4E), indicating that vessel- 
associated calcifications do not lead to inflammasome activation in 
microglia. Thus, a phenotype of CAM is distinct from DAM, although 
they share expression of selected signature genes (Fig. 2).
Microglia proliferate around vessel-associated calcifications
To further characterize microglia in Pdgfbret/ret mice, we performed 
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Fig. 1. An inflammatory microenvironment surrounds brain calcifications. (A) Samples collected for transcriptome analysis. RNA-seq was performed from tissue 
isolated from two anatomical regions of Pdgfbret/ret and control animals (n = 4). Tissue enriched with brain calcifications was isolated from the thalamus/midbrain region 
labeled as calcification-prone region. Tissue isolated from the cortex is labeled as non–calcification-prone region. (B) Volcano plot showing deregulated genes in calcification- 
prone regions in Pdgfbret/ret animals compared to control animals. (C and D) Venn diagrams showing up-regulated (C) and down-regulated (D) genes in calcification-prone 
and non–calcification-prone regions. (E) Significantly up-regulated (in red) and down-regulated (in blue) pathways identified by gene set enrichment analysis (GSEA) 
(P < 0.05) in calcification-prone regions in Pdgfbret/ret animals compared to controls. (F) For each module identified by the network analysis, the module eigengene was 
calculated, which summarizes the expression profile of the module. The M4 module is associated with calcification-prone brain regions in Pdgfbret/ret mice. Heatmap 
shows column-wise standardized (z score) module eigengene values. CPR, calcification-prone region; NCPR, non–calcification-prone region; TOM, topological overlap 
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Fig. 2. Microglia around vessel calcifications express proteins associated with a DAM/PAM signature. (A) Heatmap showing the expression of selected DAM signa-
ture genes significantly up-regulated in calcification-prone regions (thalamus/midbrain) in Pdgfbret/ret animals and controls (n = 4). Data are presented as z score. (B to 
D) Immunohistochemical validation of proteins associated with the DAM signature. (B) Iba1-positive (in red) microglia adjacent to a calcification (encircled with white 
dotted lines) are strongly positive for CD45 (in cyan) and positive for TIMP2 (in yellow). (C) Iba1-positive (in cyan) microglia surrounding osteocalcin-positive calcifications 
(in yellow) are positive for CD68 (in red). (D) Iba1-positive (in cyan) microglia surrounding osteocalcin-positive calcifications (in yellow) are positive for CLEC7A (in red). 
(E) P2RY12-positive (in cyan) resident microglia around brain calcifications (encircled with white dotted lines) express CLEC7A (in red). Double-positive cells are marked 
with yellow arrowheads. P2RY12 staining colocalizes with Iba1 (in blue) staining. (F) A subset of CAMs (CLEC7A; in cyan) express ITGAX (in red). Calcifications are surrounded 
with yellow dashed  lines. (G) Microglia (Iba1; in cyan) surrounding brain calcifications express CST7 (in red). Nuclei were visualized using 4′,6-diamidino-2-phenylindole 
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multicolor flow cytometry panel to distinguish immune cells and 
activated microglia from normal microglia. We detected eight im-
mune cell clusters both in control and Pdgfbret/ret mice, as visualized 
by a dimension reduction algorithm uniform manifold approxima-
tion and projection (UMAP) (Fig. 3A and fig. S5A) (30). Within the 
microglial cluster (fig. S5B), we defined three subclusters (homeo-
static microglia, phagocytotic microglia, and Ki67+ microglia) of 
microglia on the basis of median marker expression of seven markers 
(CD11b, Ki67, F4/80, CD64, CX3CR1, CCR5, and MerkTK) (Fig. 3, 
B and C). Overall changes in Pdgfbret/ret microglia compared to con-
trols included increased expression of CX3CR1 and reduced CCR5 
expression (fig. S5C). We also detected an increase in Ki67+ microglia 
and the emergence of CX3CR1high, MerTKhigh microglia (phagocytotic 
microglia) in Pdgfbret/ret animals (Fig. 3, A to C). Using immunohisto-
chemical staining for the proliferation marker Ki67, we confirmed 
the presence of proliferating microglia (Fig. 3D). Also in vivo label-
ing of proliferating cells using 5-ethynyl-2′-deoxyuridine (EdU) in 
control and Pdgfbret/ret mice showed EdU-positive microglial cells 
around calcifications (Fig. 3E). In addition, we detected proliferating 



















































































Fig. 3. Microglia proliferate around vessel-associated calcifications. (A to C) Tissue from calcification-prone brain regions of Pdgfbret/ret mice and controls were ana-
lyzed using flow cytometry with a panel of antibodies to identify leukocytes and subtypes of brain myeloid cells. (A) Eight subpopulations of immune cells were identified 
with UMAP analysis. Microglia are depicted in green. BAMs, border-associated macrophages. MHCII, major histocompatibility complex II. (B) Microglia [in green in (A)] were 
isolated and analyzed separately using UMAP. An increase in proliferating (Ki67+, in pink) microglia and the appearance of phagocytotic (in green) microglia in Pdgfbret/ret 
mice were observed in contrast to control animals (Pdgfbret/wt). (C) Heatmap showing the expression of markers in different microglial subpopulations used to define 
subpopulations in (B) using UMAP. n = 3. (D) CD68-positive (in yellow) microglial cell (Iba1, in cyan) surrounding brain calcification (encircled with yellow dashed lines) is 
Ki67 positive (in red). (E) EdU (in red)–labeled Iba1-positive (in cyan, yellow arrowheads) microglia around brain calcifications (encircled with yellow dashed lines). Nuclei 
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(fig. S6A), while other cell types of the NVU (endothelial cells, peri-
cytes, and astrocytes) were Ki67 negative (fig. S6, B to D). Brain 
vasculature in Pdgfbret/ret mice is permissive for leukocyte entry (31); 
therefore, we investigated whether CD45high cells with a round 
morphology (fig. S6A) surrounding calcifications could be T cells. 
Using immunohistochemistry, CD3+ T cells were detected in the 
brain parenchyma surrounding calcifications (fig. S6E) and in brain 
regions not prone to vascular calcification, e.g., in corpus callosum 
(fig. S6F). Some of these T cells were Ki67 positive (fig. S6, E and F, 
yellow arrowheads). To assess whether T cells trigger the formation 
of brain calcification, we crossed Pdgfbret/ret mice with Rag1−/− mice, 
which lack mature T cells. The absence of T cells did not prevent the 
formation of brain calcifications in Pdgfbret/ret; Rag1−/− mice (fig. S7), 
indicating that T cells, although present around brain calcifications, 
do not induce vessel calcification.
Microglia give rise to cathepsin K–expressing cells around 
vessel calcifications
We have reported previously that a subset of cells surrounding calcifi-
cations express osteoclast-associated markers receptor activator of nu-
clear factor κB (RANK) and cathepsin K (17). In addition, cathepsin K, 
which is a principal collagen I–degrading protease in bone, is deposit-
ed in brain calcifications (17). Here, we show that RANK-expressing 
cells around calcifications are positive for the microglial marker Iba1 
(Fig. 4A). To investigate whether resident microglia give rise to 
osteoclast-like cells around vessel-associated brain calcifications in 
Pdgfbret/ret mice, we crossed two inducible Cre lines (Sall1-CreERT2 and 
Cx3cr1-CreERT2) and a reporter line expressing tdTomato under the 
Rosa26 promoter (Ai14) with Pdgfbret/ret animals to genetically label 
microglia. The Cx3cr1- CreERT2 line targets CX3CR1+ macrophages 
including microglia and “border-associated” macrophages in the CNS 
(32), whereas the Sall1-CreERT2 line targets resident microglia but not 
infiltrating immune cells or brain PVM (33). Mice were treated with 
tamoxifen at 1 month of age to induce tdTomato expression and euth-
anized at 4 months of age (Fig. 4B). Immunostaining with cathepsin K 
and Iba1 showed a colocalization with tdTomato both when using the 
Cx3cr1-CreERT2 (Fig. 4C) or Sall1-CreERT2 (Fig. 4D) line, indicating 
that resident microglia respond to calcifications by expressing and de-
positing cathepsin K into vascular calcifications.
Pharmacological ablation of microglia intensifies  
vessel calcification
After establishing that cathepsin K–expressing cells surrounding 
vascular calcifications are derived from resident microglia (Fig. 4), 
we asked whether microglia actively participate in calcification- 
associated pathology. To this end, we depleted microglia in Pdgfbret/ret 
and control animals for 2 months by using the colony-stimulating 
factor 1 receptor (CSF1R) inhibitor PLX5622 (Fig. 5A). In contrast 
to mice fed with control chow, mice fed with chow containing 
PLX5622 showed a reduction in the number of microglia (fig. S8, A 
and B). We used two markers, osteocalcin and APP, to detect and 
quantify vascular calcification (Fig. 5B). We previously reported that 
cerebral vascular calcifications are positive for bone matrix proteins, 
including osteocalcin (17). Moreover, a recent study identified that 
several nonbone proteins, including APP, are enriched in vessel- 
associated calcifications (15). A noticeable increase in vascular calcifi-
cation (approximately fourfold) in Pdgfbret/ret mice was seen 2 months 
after microglial depletion (Fig. 5, B and C). In addition, calcifications 
appeared heterogeneous in size and shape in PLX5622 chow–fed 
compared to control chow–fed Pdgfbret/ret mice (Fig. 5B). In microglia- 
depleted Pdgfbret/ret mice, the staining pattern of APP and osteocalcin 
was altered. APP and osteocalcin immunostainings were stronger 
along the periphery and weaker within calcifications. Some calcifi-
cations only stained for APP, whereas others immunolabeled only 
with osteocalcin (Fig. 5B, arrowheads). However, the ratio of APP- 
and osteocalcin-positive calcifications between PLX5622-treated and 
control chow–treated Pdgfbret/ret mice was not statistically signifi-
cant (Fig. 5D). Depletion of microglia did not alter vascular density 
(Fig. 5E) or modify already impaired vascular permeability to plasma 
proteins (20, 34) in Pdgfbret/ret mice (fig. S8, D to F). CAMs express 
cathepsin K (Fig. 4, C and D). Accordingly, long-term microglial 
ablation should eliminate cathepsin K expression and deposition 
into calcifications. Microglial depletion reduced cathepsin K deposition 
in calcifications (Fig. 5, F and G). Consistent with our observation 
that activated microglia encircling calcifications do not up-regulate 
osteopontin expression (fig. S4), osteopontin is still deposited in 
calcifications in Pdgfbret/ret mice after microglial depletion (fig. S8C). 
Together, these results provide additional evidence that microglia are 
B




























Fig. 4. Microglia give rise to cathepsin K–expressing cells around calcifications. 
(A) Iba1-positive (in cyan) microglia around brain calcifications (encircled with yellow 
dotted lines) express the osteoclast marker RANK (in red). (B) Experimental setup of 
lineage tracing experiments. At 1 month of age, control and Pdgfbret/ret mice positive 
for Sall1-CreERT2; Ai14 or Cx3cr1-CreERT2; Ai14 were administered tamoxifen for five con-
secutive days and euthanized at 4 months of age. TdTomato expression was induced 
using inducible Cre lines where the expression of Cre is driven under Sall1 or Cx3cr1 
promoter. (C and D) Cathepsin K staining (in yellow) colocalizes with tdTomato (in 
red) and Iba1 staining (in cyan) adjacent to calcification (encircled with white dotted 
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the principal cell type, giving rise to osteoclast-like cells surrounding 
calcifications. In addition, our data show that microglia depletion 
aggravates the vessel-associated calcification phenotype, indicating 
that microglial activity could modify the pathophysiology of PFBC.
Microglia ablation leads to bone protein containing axonal 
spheroids in white matter
After 2 months of chronic microglial depletion in control (C57BL6, 
Pdgfbret/wt) and Pdgfbret/ret mice (Fig. 5A), we observed conspicuous 
osteocalcin staining, indicative of calcification in the internal capsule, 
thalamus, and striatum adjacent to white matter fiber tracts (Fig. 6A, 
dotted yellow areas). However, linear osteocalcin-positive structures 
were not vessel associated (Fig. 6B and movie S1). Negativity for 
Alizarin red indicated that the observed white matter deposits were 
not calcified in three-month-old mice (fig. S8G, top pink panel). 
However, this result could be due to the young age of the mice. We 
previously showed that vascular calcifications in Pdgfbret/ret mice do 
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Fig. 5. Pharmacological ablation of microglia aggravates vascular calcification. (A) Experimental setup of the pharmacological ablation of microglia. One-month-old 
mice (Pdgfbret/wt, Pdgfbret/ret, or C57BL6) were fed PLX5622 or control chow for 2 months. Mice were euthanized at 3 months of age. (B) Vessel-associated calcifications, 
visualized by osteocalcin (in red) and APP staining (in cyan), are increased in Pdgfbret/ret compared to control chow–fed Pdgfbret/ret animals. Blood vessels are visualized 
using CD31 staining (in white). Note that some calcifications in PLX5622-treated Pdgfbret/ret mice are only positive for APP (yellow arrowheads), whereas others are positive 
only for osteocalcin (magenta arrowheads). (C) Quantification of calcification number in Pdgfbret/ret mice administered PLX5622 or control chow (unpaired two-tailed 
t test; **P = 0.0087). (D) Ratio between APP- and osteocalcin-positive calcifications after PLX5622 and control chow treatment. (E) Quantification of vessel density in Pdgfbret/
ret mice with administered PLX5622 or control chow (unpaired two-tailed t test; P = 0.8782). (F) Cathepsin K (in white) deposition in calcifications (in red) in Pdgfbret/ret mice 
is reduced after PLX5622 treatment. (G) Quantification of cathepsin K intensity from immunohistochemical stains in (F) (unpaired two-tailed t test; *P = 0.0276). Control 
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Fig. 6. Microglia ablation leads to bone protein–containing axonal spheroids in white matter. (A) Coronal sections of Pdgfbret/ret mouse brains fed with control chow 
or chow containing PLX5622. Mice treated with PLX5622 exhibited conspicuous osteocalcin staining (in white) in the internal capsule (yellow dotted lines) in addition to 
calcifications in the thalamus (encircled with pink dotted lines). Coronal mouse brain section (Allen Adult Mouse Brain Atlas) depicts the location of analyzed brain sec-
tions (photo credit: Allen Institute). (B) Linear inclusions, positive for osteocalcin (in red), in white matter are not vessel associated in C57BL6 (left), Pdgfbret/wt (middle), and 
Pdgfbret/ret (right) mice. Blood vessels are visualized using the anti–collagen IV antibody (in white). (C) White matter deposits appearing in Pdgfbret/ret and control mice 
(Pdgfbret/wt) after PLX5622 treatment are positive for PAS (black arrowheads). (D) Dystrophic neurites exhibiting axonal spheroids (indicated by white arrowheads) in white 
matter after PLX5622 treatment in Pdgfbret/ret and control (Pdgfbret/wt) mice. (E to G) White matter deposits appearing after microglial depletion are positive for osteocalcin 
(in cyan) and APP (in red) (E), osteocalcin (in red) and MBP (in white) (F), and OPN (in cyan) and APP (in red) (G). Nuclei were visualized using DAPI (E, in white). C57BL6 
control chow and PLX5622 chow, n = 5. Pdgfbret/ret and Pdgfbret/wt control chow, n = 4; and PLX5622 chow, n = 3. Scale bars, 1000 mm (A), 100 mm (B), 50 mm (B pink inset, C, 















































Zarb et al., Sci. Adv. 2021; 7 : eabc4898     26 February 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 15
Accordingly, spheroidal deposits on vessels in the thalamus were 
Alizarin red negative (fig. S8G, mid blue panel, arrowheads), 
whereas occasional spheroids in the midbrain showed Alizarin red 
positivity (fig. S8G, bottom orange panel). We further characterized 
deposits in the white matter that appeared after microglial depletion 
using classical histochemical stains. Deposits were periodic acid–Schiff 
(PAS) positive, indicating the presence of glycoproteins (Fig. 6C, 
black arrowheads). The Bielschowsky silver stain revealed the pres-
ence of brown to black spheroids in the white matter, indicative 
of degenerating neurites (Fig. 6D, white arrowheads). In addition, 
costaining of osteocalcin with APP, a marker for neuronal injury, 
and with myelin basic protein (MBP) showed colocalization within 
axonal spheroids (Fig. 6, E and F). Furthermore, APP-positive 
spheroids in the white matter were also positive for another bone 
protein, osteopontin (Fig. 6G). Thus, prolonged microglial depletion 
using the CSF1R inhibitor PLX5622  in adult mice leads to white 
matter injury, characterized by the formation of axonal spheroids, 
which immunolabel with APP and MBP as well as osteopontin, in-
dicating the accumulation of bone proteins.
Microglia control vascular calcification in a  
TREM2-dependent manner
In addition to microglial depletion using a pharmacological CSF1R 
inhibitor, we used a genetic approach to impair microglial function 
in Pdgfbret/ret mice by crossing Pdgfbret/ret mice with Trem2−/− mice. 
Deletion of TREM2 leads to reduced microglial functionality (35). 
Furthermore, TREM2 expression is necessary for microglia to achieve 
the full DAM signature in a mouse model of AD (23). However, 
Trem2 is expressed in two brain-resident myeloid populations, microglia 
and PVM (36). We performed immunohistochemical detection of 
CD206+ PVM and observed that PVM are located around arteries 
and veins on the vascular tree and are not present at the capillary 
bed (fig. S9A), which is the calcified vascular bed in PFBC. Thus, we 
conclude that PVM are unlikely to play a role in a calcification pro-
cess at the capillaries. We noticed an altered pattern of calcification 
in Pdgfbret/ret; Trem2−/− mice with vessels frequently encrusted with 
multiple osteocalcin-positive nodules (Fig. 7A, bottom), yielding 
the “pearls-on-a-string” phenotype reminiscent of human PFBC 
(19). This pattern was particularly evident in rostral thalamic re-
gions that show less calcification than caudal thalamus and mid-
brain. Calcifications in Pdgfbret/ret;Trem2+/+ animals appeared as 
single nodules (Fig. 7A, bottom) in accordance with the reported 
phenotype of calcifications in Pdgfbret/ret mice (15, 17, 18). In addition 
to the altered pattern, vascular calcification was markedly aggravated 
in Pdgfbret/ret; Trem2−/− and Pdgfbret/ret; Trem2+/− mice (Fig. 7B). 
Similar to the microglia depletion experiments, we observed altered 
APP and osteocalcin immunostaining of calcifications in Pdgfbret/ret mice 
in the absence of one or two Trem2 alleles (fig. S9B). In Pdgfbret/ret; 
Trem2+/+ mice, calcifications stain uniformly with both antibodies 
used to visualize calcifications (osteocalcin and APP), whereas in 
Pdgfbret/ret; Trem2+/− and Pdgfbret/ret; Trem2−/− animals, calcifications 
showed weak APP or osteocalcin immunopositivity, respectively 
(fig. S9, B and C). Quantification of vascular calcifications (using 
positivity for both APP and OCN) in the midbrain of Pdgfbret/ret; 
Trem2−/− and Pdgfbret/ret; Trem2+/− mice showed an increased calci-
fication (four- to sixfold) compared to Pdgfbret/ret;Trem2+/+ mice 
(Fig. 7C). The lack of Trem2 in control mice did not lead to brain 
calcification (fig. S9D), alter vascular density (fig. S9, B and E), or 
affect the already altered permeability to plasma proteins in Pdgfbret/ret 
mice (fig. S9F). Thus, functional TREM2 in microglia is necessary 
to limit the formation of vessel calcifications in Pdgfbret/ret mice. In 
addition, we observed that microglia surrounding calcifications ex-
press CLEC7A, a DAM-associated protein dependent on Trem2, in 
Pdgfbret/ret;Trem2−/− animals (fig. S9G). Cathepsin K deposition into 
calcifications is TREM2 dependent; Pdgfbret/ret; Trem2+/− and Pdgfbret/ret; 
Trem2−/− mice displayed a strongly reduced cathepsin K deposition 
into calcifications (Fig. 7, D and E). In summary, these data show 
that cathepsin K expression by CAM is TREM2 dependent and further 
corroborate that microglia control the growth of vascular calcifica-
tions in the brain.
Microglia depletion or functional modulation alters 
astrocyte reactivity but not the neurotoxic-like profile 
around calcifications
We next explored whether microglia also modify the strong astrocyte 
reactivity around calcifications (17, 18). We had shown previously 
that astrocytes encircling brain calcifications exhibit a neurotoxic 
response [e.g., C3 and lipocalin-2 (LCN2) expression] and an unusual 
reactive phenotype (e.g., podoplanin expression) (17). We investigated 
whether astrocyte reactivity and the expression of neurotoxic markers are 
altered after modifying the number and function of microglia in Pdgfbret/ret 
mice. Microglia ablation using PLX5622 or compromised function 
(Trem2 genotype) in Pdgfbret/ret mice resulted in an altered staining 
pattern of GFAP and podoplanin, proteins expressed by reactive astro-
cytes surrounding calcifications (fig. S10, A and B). In Pdgfbret/ret mice 
treated with PLX5622, GFAP reactivity showed a diffuse pattern, most 
likely because of an increased density of calcifications, compared to 
mice that received control chow (fig. S10, A, E, and G). Furthermore, 
similar alterations in GFAP staining were observed in Pdgfbret/ret mice 
with impaired microglial function: Pdgfbret/ret; Trem2+/− and Pdgfbret/ret; 
Trem2−/− (fig. S10B). Podoplanin staining in reactive astrocytes sur-
rounding calcifications was markedly reduced (fig. S10, A and B). 
We quantified podoplanin and GFAP staining intensity and calculated 
the staining intensity ratio, which showed a trend toward a reduc-
tion in Pdgfbret/ret mice treated with PLX5622 (fig. S10C) and a sig-
nificant reduction in Pdgfbret/ret; Trem2+/− and Pdgfbret/ret; Trem2−/− 
mice (fig. S10D) compared to Pdgfbret/ret mice. Notably, we did not 
detect a reduction in the expression of neurotoxic signature mark-
ers LCN2 and C3 by reactive astrocytes surrounding calcifications 
after microglia depletion in Pdgfbret/ret mice (fig. S10, E and F). We 
quantified LCN2 and C3 and GFAP staining intensity and calculated 
the staining intensity ratio, which showed no significant difference 
between PLX5622-treated and nontreated Pdgfbret/ret mice (fig. S10, 
G and H). Together, these results indicate that microglia modulate 
astrocyte reactivity but are not required to evoke a neurotoxic-like 
astrocyte phenotype in response to vessel calcification.
DISCUSSION
Our results demonstrate that in addition to already known microg-
lial functions, microglia activity in the context of vascular calcifica-
tion is beneficial by identifying incipient harmful calcification. We 
have used a pharmacological approach in a mouse model for PFBC 
to modify microglial numbers and a genetic approach to modify 
microglial function. Both approaches enhance the calcification of 
the NVU (Figs. 5 and 7). Vascular calcification, resulting in in-
creased pulse wave velocity and decreased end-organ perfusion and 
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Unexpectedly, studies investigating vascular calcifications in the brain 
are rare (38). Therefore, the consequences of calcification on vascular 
function at the NVU, including neurovascular coupling, have not 
been studied. As noted, brain calcification is a common incidental 
CT finding (13). It is plausible that under homeostatic conditions, 
i.e., without underlying vascular pathology, microglia limit vascular 
calcification during aging, which should be addressed by future studies. 
Vascular calcification is commonly observed in neurodegenerative 
diseases such as AD (39), which warrants further investigation to 
determine whether microglial dysfunction contributes to vascular 
pathology in AD. Thus, in addition to parenchymal surveillance 
and the removal of various injurious stimuli, microglia could re-
move calcium phosphate precipitates and halt calcification of the 
NVU (fig. S11).
Microglial activation is insult dependent (22); however, some 
microglial activation gene signatures are shared (e.g., Spp1 and Clec7a) 
by several neurodegenerative proteinopathies, developmental stages, 
and aging-related changes (23, 24). We observed that CAMs up- 
regulate CLEC7A (Fig. 2, D and E) but not osteopontin (OPN; gene 
name, Spp1) (fig. S4, A to C) expression, indicating that calcifica-
tions elicit a microglial response similar to but distinct from DAM/
PAM and aging microglia. CLEC7A is still expressed by CAM in the 
absence of Trem2 (fig. S9F), which is necessary for the induction of 
the DAM signature in microglia (23). Furthermore, osteopontin is 
deposited in vessel calcifications after microglial depletion (fig. S8C). 
We detected a strong osteopontin expression in a subset of GFAP- 
positive astrocytes surrounding calcifications (fig. S4C), similar to 
osteopontin expression in reactive astrocytes after a stab wound injury 
(40). Osteopontin is highly expressed in injured tissues, including 
brain diseases (e.g., Parkinson disease and multiple sclerosis). One 
of the biological functions of osteopontin is to act as a hydroxyapatite 
binding mineral chaperone to inhibit the formation of hydroxyapatite 
crystals (41). The induction of osteopontin by different cells (e.g., 
microglia, astrocytes, and neurons) in response to various brain insults 
could prevent injury and ectopic calcification in the parenchyma or 
at the NVU. Ectopic soft-tissue calcifications in the periphery and 
in the brain, which are induced by excitotoxic insults, have a similar 
lamellar structure with darker-appearing lamellae rich in osteopontin 
(42). Notably, Spp1−/− mice develop severe secondary neurodegen-
eration accompanied by increased brain calcification in response to 
excitotoxic insults (43).
We show that cathepsin K deposition in vascular calcifications is 
decreased after altering microglia numbers or function in Pdgfbret/ret 
mice (Figs. 5F and 7E). Accordingly, cathepsin K–expressing cells 
surrounding vessel calcifications derive from resident microglia 
(Fig. 4, B and C). In the bone, cathepsin K is expressed and secreted 
by osteoclasts and represents the primary enzyme for degrading 
type I collagen (44). Our work and that of others have documented 
collagen I in brain calcifications (17, 45). Thus, cathepsin K activity 







































































































































































































Fig. 7. TREM2-dependent microglial function is crucial in controlling vascular calcification. (A) Altered pattern of vessel calcification in Pdgfbret/ret; Trem2−/− animals compared to 
Pdgfbret/ret; Trem2+/+ animals. Calcifications are visualized using osteocalcin staining (in red) and blood vessels using collagen IV staining (in white). (B) Pdgfbret/ret; Trem2−/− 
and Pdgfbret/ret; Trem2+/− animals show an increase in calcification load when compared to Pdgfbret/ret; Trem2+/+ animals. Vascular calcification is visualized with osteopontin 
(in red), and blood vessels are visualized using CD31 staining (in white). (C) Quantification of calcification using immunohistochemical stains [one-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparison; *P = 0.0270 and **P = 0.0018). (D) Cathepsin K (in white) deposition in calcifications (osteopontin, in red) is reduced in Pdgfbret/ret; 
Trem2−/− and Pdgfbret/ret; Trem2+/− animals when compared to Pdgfbret/ret; Trem2+/+ animals. (E) Quantification of cathepsin K intensity with immunohistochemical stains (one-way 
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for calcium phosphate precipitation. Microglia-specific modification 
of cathepsin K expression should clarify the role of cathepsin K in 
vascular calcification. Microglial activity that impedes vessel calcifi-
cation could trigger a coordinated activation of several pathways in 
protein and hydroxyapatite degradation. However, it is currently 
unclear whether microglia remove hydroxyapatite present in vascular 
calcifications (17). Macrophages have been shown to remove various 
crystals, including hydroxyapatite, which leads to activation of the 
NLRP3 inflammasome pathway (29). Our studies show that although 
vessel calcifications elicit strong microglial reactivity in vivo, they do 
not activate the inflammasome (fig. S4E). Further studies are needed 
to understand how microglia sense and remove vascular calcification 
and whether this activates intracellular pathways as those evoked by 
self-derived damage-associated molecular patterns via pattern recog-
nition receptors. In addition to altered cathepsin K deposition, we 
observed an altered deposition of APP and osteocalcin into calcifi-
cations in Pdgfbret/ret crossed with Trem2−/− or Trem2+/− or after 
microglia depletion (Figs. 5B and 7B). This finding indicates that 
microglial activity not only impedes the growth of calcifications but 
also modifies matrix composition of calcifications.
In this study, we observed that functional TREM2 is required to 
halt vessel calcification in a mouse model of PFBC (Fig. 7). TREM2 
deficiency also leads to an altered vessel calcification pattern in 
Pdgfbret/ret mice (Fig. 7A), similar to that described in human autopsy 
cases. Vascular calcification in PFBC is sometimes described as 
pearls on a string because of numerous, tiny spherical calcifications 
that encrust almost the entire abluminal side of capillaries (19, 46). 
Calcifications appear as single nodules (15–18, 47) in mouse models 
of PFBC. Variants in a microglia-specific gene, TREM2, have been 
associated with an increased risk for AD (2). Studies in mouse models 
of AD have linked functional TREM2 to the development of a spe-
cific microglia activation state, DAM (23, 48), and to maintaining 
microglial metabolic fitness as well as a sustained microglial re-
sponse to Ab plaque–induced pathology (49). It has been proposed 
that although microglia are efficient in phagocytosing protein aggre-
gates in the early stages of AD, over time, they lose their efficiency (2). 
Therefore, it is plausible that by crossing Pdgfbret/ret with Trem2+/− 
or Trem2−/−, vascular calcification is accelerated because of microglial 
exhaustion (2). It is noteworthy that microglia encircling calcifica-
tions contain numerous phagocytotic vesicles (15), and also, our study 
identified a population of phagocytotic microglia in the calcified brain 
regions in Pdgfbret/ret mice (Fig. 3, B to E). Further studies are needed 
to understand whether TREM2-driven microglial function is initiated 
because of altered proteostasis and calcification at the NVU or neu-
ronal death occurring because of altered vessel function. These pro-
cesses, however, are not necessarily mutually exclusive.
Several lines of evidence indicate that cell-autonomous defects in 
microglia lead to brain disease and cerebral calcification (50). 
Microglia have also emerged as a disease modifier in a wide range of 
neurodegenerative diseases (e.g., AD and frontotemporal demen-
tia) (2). Of six genes implicated in PFBC (JAM2, PDGFB, PDGFRB, 
SLC20A2, XPR1, and MYORG), microglia express JAM2, PDGFB, 
SLC20A2, and XPR1. Although microglia express PDGFB, they do 
not express the receptor PDGFRB. Thus, it is unlikely that PDGFB 
or PDGFRB haploinsufficiency in PFBC causes cell-autonomous 
microglial dysfunction. Phosphate importer SLC20A2 and exporter 
XPR1 are expressed ubiquitously in the brain, and their specific role 
in microglia has not been investigated. However, it has been reported 
that in zebrafish, xpr1b, an ortholog of XPR1, is crucial for the dif-
ferentiation of tissue-resident macrophages and microglia (51). In 
mice, the full knockout of Xpr1 is embryonic lethal (52), but whether 
the absence of Xpr1 affects microglia development has not been as-
sessed. Thus, further studies are needed to dissect the role of PFBC 
genes in microglial function.
In this study, on the basis of positivity for osteocalcin, we found 
by serendipity that microglial ablation by chronic CSF1R inhibition 
using PLX5622 for 2 months resulted in localized axonal damage to 
fiber tracts of the internal capsule and adjacent thalamic and striatal 
areas (Fig. 6). Positive staining for osteocalcin and osteopontin co-
incided with the presence of dystrophic neurites exhibiting spher-
oid formation (Fig. 6, E to G), similar to the pathology described 
in patients with leukoencephalopathy caused by CSF1R mutations 
(50). These patients exhibit brain calcification in white matter re-
gions and a reduction in microglia in affected regions. It is plausible 
that axonal spheroids become calcified during the course of the 
disease. Further studies are needed to understand the relationship 
between the appearance of axonal spheroids positive for bone pro-
teins and white matter calcification. We observed that inclusions 
within dystrophic neurites stain positive for MBP (Fig. 6G), a pro-
tein secreted by oligodendrocytes, indicating a disrupted homeostasis 
in oligodendrocytes. Previous studies on white matter microglia have 
shown that microglia promote myelinogenesis during early devel-
opment, providing evidence for a role in optimizing oligodendrocyte 
function (53). Thus, further studies are needed to ascertain whether 
axonal damage is directly caused by a reduction in microglia or the 
absence of microglia has an effect on another cell type (e.g., oligo-
dendrocytes), which may enhance spheroid formation in neurites.
In conclusion, we describe an unrecognized role of microglia in 
brain vascular calcification. In addition, we show that functional 
microglia are important to prevent calcification of the NVU in neu-
rodegenerative diseases with a compromised NVU. Proposed mecha-
nisms by which microglia control vascular calcification include the 
removal of apoptotic cells and spontaneous calcium phosphate pre-
cipitates as well as the prevention of nucleation of hydroxyapatite 
by controlling proteostasis of the ECM and/or the secretion of anti-
calcifying proteins or molecules.
MATERIALS AND METHODS
Mice
Mice used in this study were 1 to 5 months old. Both sexes were used for 
experiments. The following mouse strains were used: C57BL6/J (Charles 
River Laboratories), B6.Pdgfbtm3Cbet (Pdgfbret/ret) (18, 54), Cx3cr1-CreERT2 
(55), Sall1-CreERT2 (33), B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J 
(Ai14) (Jackson Laboratory, stock no. 007914), APP/PS1 (56), Rag1−/− 
(57), and Trem2−/− (58). This study was carried out in accordance 
with study protocols approved by the Cantonal Veterinary Office Zurich 
(permit numbers ZH196/2014 and ZH151/2017).
In vivo treatments
Tamoxifen treatment for the genetic labeling of Cx3Cr1- and 
Sall1-expressing cells
For tamoxifen-inducible labeling of Cx3cr1- and Sall1-expressing 
cells in respective genotypes (Cx3cr1-CreERT2; Ai14Tg/wt; Pdgfbret/ret 
or Pdgfbret/wt and Sall1-CreERT2; Ai14Tg/wt; Pdgfbret/ret or Pdgfbret/wt), 
4-week-old animals were treated for five consecutive days via oral 
gavage with 2 mg of tamoxifen (Sigma-Aldrich, catalog no. T5648) 
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Pharmacological ablation of microglia
Oral CSF1R inhibitor, PLX5622 (Plexxikon Inc.), was formulated in 
AIN-76A standard chow by Research Diets (New Brunswick, NJ) at 
1200 parts per million. Control mice received AIN-76A chow with-
out PLX5622. PLX5622 chow and control chow were provided by 
Plexxikon Inc. under a material transfer agreement. One-month-
old mice were fed with chow containing PLX5622 or control chow 
for 2 months and euthanized at the age of 3 months.
EdU treatment
Three-month-old mice were injected with EdU (50 mg/kg; Sigma- 
Aldrich, catalog no. 900584) intraperitoneally for three consecutive 
days and euthanized on the following day.
Antibodies
Primary antibodies used for immunofluorescence staining are listed 
in table S1. All secondary antibodies (suitable for multiple labeling) 
labeled with various fluorophores (Alexa Fluor 488, Cy3, and DyLight 
649) made in donkey (anti-rabbit, anti-rat, and anti-goat) or in goat 
(anti-chicken Cy3) were purchased from Jackson Immuno Research. 
Antibodies used for flow cytometry analysis are listed in table S2.
Histochemistry and immunohistochemistry
Immunohistochemistry was performed according to methods de-
scribed previously (17). For EdU detection, the Click-iT EdU Alexa 
Fluor 555 imaging kit (Thermo Fisher Scientific) was used, and slices 
were treated according to the manufacturer’s instructions. Immuno-
histochemical stainings were imaged with a confocal microscope 
[Leica SP5 or SP8; 20× numerical aperture (NA), 0.7; 40× NA, 1.25; 
and 63× NA, 1.4] or stereomicroscope (Zeiss Axio Zoom.V16; 1× NA, 0.25). 
For stains that exhibited salt-and-pepper noise, a median filter of 5 × 5 × 5 
was applied to eliminate noise. Images were analyzed using the image 
processing software Imaris 9.2.0. (Bitplane) and Adobe Illustrator CS6.
For histochemistry, mouse brains were collected and embedded 
in paraffin. Two-micrometer-thick tissue sections were stained with 
PAS, hematoxylin and eosin, or the Bielschowsky silver stain using 
standard protocols. For Alizarin red staining, sections were depar-
affinized and rehydrated, as well as incubated for 1 hour in 1% Alizarin 
red solution (pH 9.0) followed by 1 hour in 1% Alizarin red solution 
(pH 6.4) at room temperature. Stained paraffin sections were scanned 
with NanoZoomer HT (Hamamatsu Photonics), equipped with a 20× 
objective (UPlanSApo; NA, 0.75; Olympus). Images were analyzed 
using Digital Image Hub software (SlidePath) and Adobe Illustrator CS6.
Detection of aggregated proteins
Paraffin-embedded 6-mm-thick brain sections were used from Pdgfbret/ret 
and controls of 1 year of age or older. As a positive control, paraffin- 
embedded sections from APP/PS1 mice (56) were used. Sections were 
deparaffinized and hydrated, followed by a 30-min incubation with 
LCO h-HTAA (27) at room temperature. For thioflavin T (Sigma- 
Aldrich, T3516) staining, deparaffinized sections were processed 
according to the manufacturer’s instructions. Congo red staining 
was performed according to standard protocol. Stained sections 
were imaged with a confocal microscope (Leica SP5; 20×; NA, 0.7) 
or Axioplan (Zeiss; 20×; NA, 0.5). Images were analyzed with image 
processing software Imaris (Bitplane).
Quantification of immunofluorescent stainings
Images for quantification of brain calcifications, cathepsin K inten-
sity, vessel density, and astrocyte reactivity were acquired using a 
20× objective (NA, 0.7; Leica SP5) 42 z-stacks with a 1.48-mm step 
and 512 × 512 pixel resolution. For quantification of total brain calci-
fication, z-stacks of APP staining and osteocalcin were summed in 
Fiji (ImageJ). Imaris software was used to quantify calcification using 
the function “surfaces.” Quantification of calcifications was performed 
in mid-midbrain, which shows the smallest interindividual variation 
in calcification load (17). Cathepsin K intensity density was calcu-
lated using Fiji (ImageJ) software. Vessel density was quantified using 
CD31 staining. The analysis was performed with a vessel density 
plugin (version1.1; with minor modifications) in Fiji (ImageJ) soft-
ware. Astrocyte reactivity was quantified using GFAP, podoplanin, 
LCN2, and C3 staining in Fiji (ImageJ). The LCN2 and C3 signal 
intensity was first masked to GFAP staining to eliminate nonastrocytic 
expression or deposition. Signal intensity was then normalized to the 
GFAP signal. Two technical replicates were quantified for each animal.
Images used for quantification of extravasated fibrinogen were 
acquired using a 20× objective (NA, 0.75, Leica SP8), seven z-stacks 
with a 1.04-mm step, and 1024 × 1024 pixel resolution. CD31 staining 
marking blood vessels was thresholded and despeckled, afterward 
subtracted from the thresholded fibrinogen staining. Image subtrac-
tion was performed to eliminate any signal inside the vessel lumen. 
Quantification of extravasated fibrinogen was performed using Fiji 
(ImageJ) software.
Microglia were quantified on images acquired using a 20× objective 
(NA, 0.7; Leica SP5), 41 z-stacks with a 0.64-mm step, and 1024 × 
1024 pixel resolution. Quantification of microglia was performed 
using the morpholibJ package in Fiji.
Flow cytometry analysis
Mice were deeply anesthetized using a mixture of ketamine and 
xylazine and perfused transcardially using ice-cold phosphate-buffered 
saline (PBS). Subsequently, mouse brains were dissected into non–
calcification-prone brain regions, i.e., cortex, hippocampus, and cere-
bellum, and calcification-prone regions, i.e., thalamus, midbrain, 
and pons. Brain cell suspensions were prepared by cutting the tissue 
into small pieces, followed by collagenase type IV treatment. Dissoci-
ated tissue was passed through an 18-gauge syringe to obtain a 
homogeneous cell suspension and further enriched with a Percoll 
gradient. Samples were then passed through a 70-mm filter, followed 
by red blood cell lysis and antibody staining. Flow cytometric anal-
ysis was carried using FACSymphony (BD Biosciences) and ana-
lyzed with FlowJo and R software.
High-dimensional analysis
Raw data were preanalyzed with FlowJo, subsequently transformed 
in MATLAB using cyt3, and percentile-normalized in R. Dimension-
ality reduction was achieved by UMAP. FlowSOM was used for auto-
mated and expert-guided cell clustering. Median marker expression 
was projected onto UMAP to generate a heatmap of median expres-
sion values.
Isolation of vessel calcifications and RNA-seq
Mice were deeply anesthetized and transcardially perfused with ice-
cold PBS. Brains were removed, placed in RNAlater Stabilization 
Solution (Thermo Fisher Scientific, catalog no. AM7020), and 1-mm 
coronal sections were cut using a brain matrix (RBMA-200C, 
World Precision Instruments). Calcifications were detected on the 
basis of their autofluorescence using a fluorescent stereomicroscope 
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surrounding tissue. Cortical sections were also removed as examples 
of non–calcification-prone regions. RNA was isolated with a micro 
RNA kit (Qiagen) according to the manufacturer’s instructions. 
The concentration of RNA and sample purity were assessed using a 
2100 Bioanalyzer (Agilent) and RNA 6000 Pico Kit (Agilent). RNA 
samples were poly(A)-enriched, and libraries were prepared using the 
Illumina TruSeq Stranded RNA kit. RNA was sequenced on an Illumina 
platform HiSeq 4000 at the Functional Genomic Center Zurich 
(UZH, ETH). The Illumina single-read approach (1 × 125 base pair) 
was used to generate raw sequencing reads with a depth of 20 million 
to 30 million reads per sample.
Bioinformatics analysis
Quantification of RNA-seq data was performed using kallisto. 
Briefly, target transcript sequences were obtained from ENSEMBL 
(GRCm38.p6), and the abundance of transcripts was quantified 
using kallisto 0.44.0 with sequence-based bias correction. All other 
parameters were set to default when running kallisto. Kallisto’s 
transcript-level estimates were further summarized at the gene level 
using tximport 1.8.0 from Bioconductor.
For downstream analysis, genes of low abundance were filtered 
out, and unwanted variation was estimated using the RUVr function-
ality from the RUVseq 1.16.0 package within Bioconductor. The 
number of factors of unwanted variation estimated from the data 
was set to 3, and the genes_by_samples matrix of residuals was 
obtained from a first-pass quasi-likelihood negative binomial gen-
eralized log-linear regression of the counts on biological covariates 
using the edgeR package from Bioconductor.
Differential expression analysis was performed using DESeq2 
1.22.0 from Bioconductor, with estimated factors of unwanted varia-
tion included as additional covariates in the design formula. Signif-
icant genes were identified using FDR < 0.05 and fold change > 2.
Coexpression network analysis was performed on the combination 
of 16 samples (4 groups × 4 replicates) using weighted correlation net-
work analysis (WGCNA) R package. Briefly, normalized count data ob-
tained from RUVseq were first adjusted for mean-variance trend using 
the regularized log transformation of DESeq2 1.22.0 from Bioconductor. 
To exclude uninformative genes from coexpression analysis in an unbi-
ased manner, 867 highly variable genes were selected on the basis of the 
overall distribution of coefficients of variation. Subsequently, a signed 
weighted network of highly variable genes was constructed using bi-
weight midcorrelation with beta = 23 as soft thresholding power. Hierar-
chical clustering of the topological overlap matrix dissimilarity further 
revealed six modules of positively correlated genes. Module eigengene 
was defined as the first PC of the expression matrix of the corresponding 
module. Module membership was defined per gene as the Pearson cor-
relation of gene expression and module eigengene. In the context of 
module membership, gene significance was defined as the geometric 
mean of the absolute value of pairwise Welch’s t statistics comparing 
Pdgfbret/ret CPR (calcification-prone region) to Pdgfbret/ret NCPR (non–
calcification-prone region), control NCPR, and control CPR. To identify 
hub genes associated with brain calcification, we computed module 
membership and gene significance, as defined above, for each gene be-
longing to the module associated with brain calcification (i.e., M4).
Gene set enrichment analysis (GSEA) was performed using the 
fgsea 1.8.0 package from Bioconductor with signal-to-noise ratio as 
defined in (59) as gene-level statistic. Before GSEA, mouse genes 
were converted to human orthologs using biomaRt 2.38.0 from Bio-
conductor. If a human ortholog was associated with more than one 
mouse gene, then the mouse gene with the maximum mean expres-
sion was selected using the collapseRows functionality within the 
WGCNA R package. Signaling pathways analyzed by GSEA were 
obtained from the Hallmark gene sets of the MSigDB. Gene signature 
of DAM and PAM were obtained from literature (23, 24). Heatmaps 
were generated using the pheatmap R package, with clustering dis-
tance and method set to Euclidean and ward.D2, respectively.
Statistical analysis
Quantified values are represented as means ± SEM. The following 
statistical tests were performed with Prism8 software (GraphPad). 
Normality was assessed using a Shapiro-Wilk test. The following 
tests were used to calculate statistical significance: Student’s t test 
(unpaired and two tailed), one-way analysis of variance (ANOVA) 
with Dunnett’s multiple comparison, or Mann-Whitney two-tailed 
test. P values < 0.05 were considered significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/9/eabc4898/DC1
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